Assessing the risk of breast cancer.
暂无分享,去创建一个
B. Weber | A. Eisen | K. Armstrong | A Eisen | K Armstrong | B Weber
[1] J Benichou,et al. Proportion of breast cancer cases in the United States explained by well-established risk factors. , 1995, Journal of the National Cancer Institute.
[2] M. Somerfield,et al. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Eddy. Screening for breast cancer. , 1989, Annals of internal medicine.
[4] M. Badzioch,et al. RISK OF FAMILIAL BREAST CANCER , 1984, The Lancet.
[5] P. Ganz,et al. Agreement between breast cancer risk estimation methods. , 1996, Journal of the National Cancer Institute.
[6] Cancer families: what risks are they given and do the risks affect management? , 1996, Journal of medical genetics.
[7] M. Gail,et al. Risk-based recommendations for mammographic screening for women in their forties. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] K. Offit,et al. Quantitating familial cancer risk: a resource for clinical oncologists. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D J Schaid,et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. , 1999, The New England journal of medicine.
[10] W D Dupont,et al. Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.
[11] E. Lustbader,et al. Validation of a breast cancer risk assessment model in women with a positive family history. , 1994, Journal of the National Cancer Institute.
[12] F. Speizer,et al. Cohort studies of fat intake and the risk of breast cancer--a pooled analysis. , 1996, The New England journal of medicine.
[13] M. King,et al. PRACTICAL GUIDE FOR ESTIMATING RISK FOR FAMILIAL BREAST CANCER , 1983, The Lancet.
[14] C A Kelsey,et al. Benefits versus risks from mammography: A critical reasessment , 1996, Cancer.
[15] R. Shore,et al. The risk of breast cancer after irradiation of the thymus in infancy. , 1989, The New England journal of medicine.
[16] S. Pauker,et al. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. , 1999, Archives of internal medicine.
[17] J. Freudenheim,et al. Lactation history and breast cancer risk. , 1997, American journal of epidemiology.
[18] K M Kuntz,et al. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. , 1997, The New England journal of medicine.
[19] Caroline S. Fox,et al. Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women , 1992, Annals of Internal Medicine.
[20] D. Bentley,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.
[21] F. Speizer,et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. , 1998, JAMA.
[22] P. Rowe. ACS orders mammography for younger women , 1997, The Lancet.
[23] D Spiegelman,et al. Validation of the Gail et al. model for predicting individual breast cancer risk. , 1994, Journal of the National Cancer Institute.
[24] T. Sellers,et al. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. , 1995, American journal of public health.
[25] Lisa M. Schwartz,et al. The Role of Numeracy in Understanding the Benefit of Screening Mammography , 1997, Annals of Internal Medicine.
[26] S. Shapiro,et al. Case-control study of oral contraceptive use and risk of breast cancer. , 1996, American journal of epidemiology.
[27] J Benichou,et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.
[28] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[29] Graham A. Colditz,et al. Risk factors for breast cancer according to family history of breast cancer , 1996 .
[30] Postmenopausal hormone therapy and mortality. , 1997 .
[31] M. Gail,et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.
[32] M. Stefanek. Bilateral prophylactic mastectomy: issues and concerns. , 1995, Journal of the National Cancer Institute. Monographs.
[33] Kristin Anderson,et al. The Role of Hormone Replacement Therapy in the Risk for Breast Cancer and Total Mortality in Women with a Family History of Breast Cancer , 1997, Annals of Internal Medicine.
[34] S. Cummings,et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.
[35] R. Hendrick,et al. Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials. , 1997, Journal of the National Cancer Institute. Monographs.
[36] J Chang-Claude,et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.
[37] G A Colditz,et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. , 1995, The New England journal of medicine.
[38] N. Risch,et al. Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994 .
[39] D. Easton,et al. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. , 1995, American journal of human genetics.
[40] P. Hartge,et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.
[41] W D Flanders,et al. The lifetime risk of developing breast cancer. , 1993, Journal of the National Cancer Institute.
[42] R. Thompson,et al. Revisions in the risk‐based breast cancer screening program at group health cooperative , 1990, Cancer.
[43] C. Weinberg,et al. Population attributable fraction estimation for established breast cancer risk factors: considering the issues of high prevalence and unmodifiability. , 1998, American journal of epidemiology.
[44] C. Christiansen,et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.
[45] F. Couch,et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.
[46] W. Chow,et al. Underreporting and Misclassification of Urinary Tract Cancer Cases on Death Certificates , 1996, Epidemiology.
[47] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.
[48] T. Powles,et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.
[49] P. Boyle,et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.
[50] D P Byar,et al. Estimating the population attributable risk for multiple risk factors using case-control data. , 1985, American journal of epidemiology.
[51] K. Kerlikowske,et al. Cost-Effectiveness of Extending Screening Mammography Guidelines To Include Women 40 to 49 Years of Age , 1997, Annals of Internal Medicine.